share_log

AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer

AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

阿斯利康 | 6-K:外国发行人报告
SEC announcement ·  04/02 07:59
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息